CD274 and cancer: An increase in LDNs commonly exists in the more advanced cancer stages and these LDNs often express the immunosuppressive surface marker, PD-L1, greater expression of neutrophil activation markers, formation of neutrophil extracellular traps (a.k.a. NETosis) and the release of ROS.